GlassScriptPhysician profile
Jennifer E Guss
NPI 1801907563
$1,866.39
in general payments reported to CMS, 2019-2025
24 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $91.54 · 2021: $79.44 · 2022: $66.05 · 2023: $542 · 2024: $363 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.43 | 2019-2025 | Airsupra, Farxiga |
| Endomagnetics LTD | $211.40 | 2023 | Magtrace, Magseed |
| Pfizer INC. | $201.09 | 2024-2025 | |
| Amgen INC. | $84.54 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $63.65 | 2019-2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $54.76 | 2023-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $48.59 | 2023-2024 | Inspire |
| Novo Nordisk INC | $47.94 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $45.28 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $40.93 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $35.52 | 2024-2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Dynavax Technologies Corporation | $31.76 | 2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2023 | Trintellix |
| Amarin Pharma, INC. | $30.08 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $27.49 | 2025 | Zenpep |
| Exact Sciences Corporation | $23.89 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.37 | 2022 | |
| Astellas Pharma US INC | $18.80 | 2024 | Veozah |
| Vertical Pharmaceuticals, LLC | $16.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.03 | 2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2020 | |
| Allergan, INC. | $11.40 | 2019 | |
| Genentech USA, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Guss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.